

Best-value biological (BVB) medicines / Best-value medicines (BVM) 2024

The HSE-Medicines Management Programme has identified the following medicines for which it may conduct a best-value biological (BVB) medicine or best-value medicine (BVM) process in 2024:

Biological Medicines

- Adalimumab (L04AB04)
- Eculizumab (L04AA25)
- Etanercept (L04AB01)
- Filgrastim (L03AA02)
- Follitropin alfa (G03GA05)
- Lipegfilgrastim (L03AA14)
- Liraglutide (A10BJ02)
- Natalizumab (L04AA23)
- Pegfilgrastim (L03AA13)
- Somatropin (H01AC01)
- Somatrogen (H01AC08)
- Teriparatide (H05AA02)
- Tocilizumab (L04AC07)
- Ustekinumab (L04AC05)

Non-Biological Medicines

- Abiraterone (L02BX03)
- Bicalutamide (L02BB03)
- Cinacalcet (H05BX01)
- Deferasirox (V03AC03)
- Fulvestrant (L02BA03)
- Glatiramer (L03AX13)
- Icatibant (B06AC02)
- Lenalidomide (L04AX04)
- Pirfenidone (L04AX05)
- Pomalidomide (L04AX06)
- Posaconazole (J02AC04)
- Sildenafil (G04BE03)
- Sunitinib (L01EX01)
- Voriconazole (J02AC03)